iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

Last updated: May 19, 2025
Sponsor: Radboud University Medical Center
Overall Status: Active - Recruiting

Phase

2

Condition

Aspergillosis

Treatment

Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)

Clinical Study ID

NCT06244979
115136
2023-509744-10-00
  • Ages > 18
  • All Genders

Study Summary

This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection.

The incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like [68Ga]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, [68Ga]Ga-DFO-B PET/CT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. The patient is at least 18 years old on the day of inclusion.

  2. The patient has suspected chronic pulmonary aspergillosis or ABPA.

  3. There is no significant interference with standard care and follow-up.

Exclusion

Exclusion Criteria:

  1. The patient is pregnant or planning on becoming pregnant.

  2. The patient has severe kidney dysfunction with eGFR < 30 ml/min/kg and/or receivesdialysis.

  3. The patient has (chronic) iron overload.

  4. The patient has been receiving antifungal treatment for more than 48 hours prior tothe study day.

  5. The patient is not able to lie still in the scanner.

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
Phase: 2
Study Start date:
May 01, 2025
Estimated Completion Date:
May 01, 2026

Connect with a study center

  • RadboudUMC

    Nijmegen,
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.